Femasys (FEMY) investor relations material

Innovative product portfolio

• Market-first, clinically validated devices for fertility and permanent birth control, supported by over 200 patents.

• Solutions designed for safe, in-office procedures with regulatory approvals in the U.S., Europe, and select global markets.

• Portfolio includes FemaSeed for first-line fertility, FemBloc for non-surgical permanent birth control, and FemVue/FemCerv for diagnostics.

• Commercial infrastructure enables rapid adoption and expansion across OB/GYN practices.

Market opportunity and growth drivers

• Addressing massive unmet needs: ~10M U.S. women with infertility and ~13M seeking permanent contraception.

• Record-low fertility rates and increased demand for contraception post-Roe v. Wade.

• Limited competition and favorable policy trends create strong tailwinds for growth.

• Revenue inflection expected from expanding access and adoption in OB/GYN offices.

Clinical and economic advantages

• FemaSeed delivers double the pregnancy rate per cycle compared to IUI, with most pregnancies in 1–2 cycles and no safety concerns.

• FemBloc offers a non-surgical, in-office alternative to sterilization, with 0% pregnancy rate in early studies and only mild adverse events.

• Both products provide cost-effective, cash-pay opportunities and are expected to be reimbursed, enhancing practice profitability.

• Seamless integration into existing workflows without additional staffing needs.